Ampliphi Biosciences Corp (NYSEAMERICAN:APHB) was the recipient of a large decrease in short interest in the month of January. As of January 31st, there was short interest totalling 945,998 shares, a decrease of 18.7% from the January 12th total of 1,163,534 shares. Based on an average daily volume of 801,494 shares, the short-interest ratio is currently 1.2 days. Currently, 10.1% of the company’s stock are short sold.

Ampliphi Biosciences (NYSEAMERICAN:APHB) opened at $1.16 on Monday. Ampliphi Biosciences has a 1-year low of $0.67 and a 1-year high of $5.80. The company has a market cap of $15.33, a price-to-earnings ratio of -0.11 and a beta of 3.20.

Ampliphi Biosciences (NYSEAMERICAN:APHB) last issued its quarterly earnings data on Tuesday, November 14th. The biotechnology company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.37. Ampliphi Biosciences had a negative net margin of 2,050.00% and a negative return on equity of 31.85%.

Separately, HC Wainwright set a $5.00 price objective on shares of Ampliphi Biosciences and gave the stock a “buy” rating in a report on Wednesday, November 15th.

COPYRIGHT VIOLATION NOTICE: This news story was originally published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The correct version of this news story can be accessed at

About Ampliphi Biosciences

AmpliPhi Biosciences Corporation is a biotechnology company. The Company is focused on the discovery, development and commercialization of phage therapeutics. The Company is engaged in identifying, characterizing and developing naturally occurring bacteriophages with its collaboration partners in bacteriophage biology, synthetic biology and manufacturing, to develop second-generation bacteriophage products.

Receive News & Ratings for Ampliphi Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampliphi Biosciences and related companies with's FREE daily email newsletter.